lap between asthma and COPD; ii) their episodic or transient overlap; iii) their structural similarities; and iv) common therapeutic targets for both conditions.
INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are pulmonary disorders characterized by various degrees of airflow limitation, inflammation, and tissue remodeling. Bronchial asthma, an allergic disease that develops in childhood, is physiologically characterized by reversible airflow obstruction. It has an episodic course and a generally favorable prognosis, as it responds well to anti-inflammatory treatment. 1 In contrast, pure COPD is caused by tobacco smoke, develops in mid-life or later, and is characterized by incompletely reversible airflow limitation that results in a progressive decline in lung function and leads to premature death. These definitions describe the physiological and anatomic extremes of asthma and COPD, and allow them to be recognized as distinct disease entities. However, in clinical practice, many older patients have pathobiological and symptomatic features of both diseases, necessitating a reevaluation of the concept of COPD and asthma as separate conditions. 2, 3 Asthma and COPD are both chronic inflammatory lung diseases. In both conditions, inflammation is associated with structural alterations at large and small airway levels. 4, 5 This can result in a transient phenotypic overlap or a combined syndrome with characteristics of both diseases.
In this review, we focus on the inflammatory mechanisms of asthma and COPD. We address: i) the importance of the over-
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So Ri Kim, 1,2 Yang Keun Rhee 1 al hyperresponsiveness) may be useful in differentiating disease characteristics and in understanding similarities in the development and progression of both obstructive airway diseases. A recent study found that 17% to 19% of patients with obstructive airway diseases had more than one condition, or overlap. 11 The overlap of asthma and COPD has been confirmed in older patients by objective testing and is becoming an important clinical consideration. 12 The distinction between the inflammatory profiles of asthma and COPD may be blurred under certain circumstances. Classically, asthmatic airways show a CD4 + lymphocyte-, eosinophil-, and macrophage-rich inflammatory response, whereas prominent increases in CD8 + T cells, neutrophils, and macrophages are seen in the bronchioles and alveoli in COPD. However, compared with mild and moderate asthmatics, severe asthmatics or asthmatics who smoke show higher numbers of neutrophils in bronchoalveolar lavage fluid and biopsies. 13, 14 Conversely, in COPD patients, especially those with acute disease exacerbations, tissue eosinophilia is common 15 and is associated with a favorable response to steroid therapy. 16 In asthmatics, there is a predominance of Th2 cytokines, including interleukin (IL)-4, IL-5, and IL-13, and upregulation of chemokines, including regulated on activation, normal T-cellexpressed and secreted (RANTES), eotaxins, and monocyte chemoattractant protein-1. 17 In contrast, Th1-dominated responses such as enhanced production of interferon-γ by CD8 + cells have been documented in COPD patients. Additionally, the main inflammatory mediators involved in the pathogenesis of tissue inflammation in COPD are the neutrophil chemokine IL-8, leukotriene B4, IL-1, and tumor necrosis factor-α. 4, 18, 19 However, in some COPD subjects, the levels of tumor necrosis factor-α indicated the presence of asthma, 20, 21 and allergic inflammatory mediators such as IL-4, IL-5, and IL-13 were produced, particularly during exacerbations.
Alveolar inflammation and the development of lung emphysema are major characteristics of COPD. The distal lung, including the alveolar parenchyma, is an important site of inflammation in asthma, although asthma is classically considered as a chronic inflammatory disease of the airways. 22, 23 Remodeling of various structural components such as airway epithelium, airway smooth muscle, vessel, mucous gland, and extracellular matrix is prominent in asthmatic airways. 24 The pathological changes within the airways that are associated with asthma and COPD are similar. 25, 26 Based on the complexities of the relationships among the clinico-pathobiological features of the two diseases, the 'Dutch hypothesis' was proposed and updated. 27 This hypothesis suggests that asthma and COPD are different expressions of a single disease entity. In contrast, the 'British hypothesis' states that asthma and COPD are separate clinical entities with similar symptoms. 28 The general consensus under either hypothesis is that similar mechanisms are involved in the pathogenesis of both diseases.
EPISODIC (TEMPORAL) CONVERGENCE OF ASTHMA AND COPD Exacerbation/infection: Changes in inflammatory features and cytokine profiles
Exacerbations of asthma and COPD are clinically significant events. They are frequently triggered by viral infections of the airways and are associated with a decline in lung function and symptomatic aggravation. 6 During exacerbation, airway inflammation becomes more exaggerated than in the mild and stable disease states, and the inflammation pattern changes. 29 Neutrophil recruitment is a prominent feature of acute exacerbation of chronic asthma, 30 probably owing to respiratory tract infection by viruses. 31, 32 Furthermore, neutrophilic inflammation in the absence of eosinophils is largely present in sudden-onset fatal asthma, and neutrophil numbers are highly elevated in status asthmaticus. 30, 33 Thus, severe and fatal asthma may be mediated by neutrophils, which is quite different from the classical Th2-driven eosinophilic form of the disease. In COPD patients, an allergic profile of inflammation can occur, particularly during exacerbation. Airway eosinophilia is observed in chronic bronchitic patients with exacerbation and is associated with the upregulation of RANTES in the airway epithelium. 15, 34 Recently, Siva et al. 35 demonstrated that the minimization of eosinophilic airway inflammation was associated with a reduction in severe COPD exacerbation. Taken together, these studies indicate that the inflammatory characteristics of asthma and COPD are interchangeable during exacerbation and infection.
The cytokine profile is also affected by disease severity. During exacerbation, Th1/Th2 patterns are reversed to some degree in each disease. Several studies have demonstrated that the levels of IL-17, a cytokine that has been actively investigated in conditions of chronic airway inflammation such as asthma, [36] [37] [38] [39] were elevated in asthma and COPD and were correlated with the presence of neutrophils and the severity of loss of lung function. An elevated IL-17A level was associated with increased neutrophilic inflammation during severe asthma or acute exacerbation. 39 Increased IL-17A was also correlated with increased airway hyperresponsiveness in asthmatics. 40 These findings imply that IL-17 is an important mediator in neutrophilic asthma. In COPD, the role of IL-17 remains unclear, although the importance of IL-17 in stimulating chemokine production and the role of neutrophils and macrophages in promoting COPD pathogenesis suggest a potential connection. 41 Disease exacerbation in both asthma and COPD can lead to an accelerated decline in lung function. 42, 43 Previous reports have shown an association between severe asthma exacerbation and an accelerated decline in forced expiratory volume in 1 s (FEV1), to a degree similar to that seen with smoking and COPD. 44 Another important observation was that the decline in FEV1 seen in patients with infrequent exacerbation was similar to that in a population without asthma. These findings suggest http://e-aair.org that repetitive episodes of exacerbation may result in fixed airflow obstruction in asthma and contribute to the phenotypic overlap between asthma and COPD.
CONVERGENCE OF ASTHMA AND COPD ON A CONTINUUM
Severe/refractory asthma: Alveolar (parenchymal) destruction Destructive changes to the alveolar parenchyma, as in emphysema, are a representative characteristic of COPD. 45 Emphysema is initially centrilobular, but can become panlobular in severe forms of the disease. In asthma, structural changes such as abnormal alveolar attachments and a decrease in elastic fibers can occur in the parenchyma, but these seem to be localized to the peribronchiolar spaces. 46 These changes lead to decreased distensibility and increased collapsibility in asthmatic emphysema, whereas loss of elastic recoil is an important factor in the dynamic collapse of the airway in COPD. 47 Currently, it is believed that there are at least two major pathophysiological mechanisms responsible for the development of emphysema: protease-antiprotease imbalance and apoptosis of structural cells. 48 Increased elastin degradation and enhanced expression of proteases have been documented in asthma patients. 22, 25 In IL-13-overexpressing transgenic mice, IL-13 induced emphysema and the expression of a variety of matrix metalloproteinases (MMPs) and cathepsins. 49 Interventions that neutralized MMPs or cathepsins dramatically ameliorated IL-13-induced emphysematous responses. This suggests that IL-13, which is implicated in the pathogenesis of asthma, has the ability to induce an alveolar remodeling response in asthmatics. In human asthma patients, the numbers of eosinophils, CD4 + Tcells, and macrophages were increased in alveolar tissue at the time symptoms appeared. 50, 51 Taken together, these data indicate that the destruction of distal airways is a consequence of a chronic, long-lasting injury which can significantly affect lung function in both COPD and asthma. Furthermore, the degree of eosinophilic inflammation correlated positively with lung volume in asthma. 
Asthma-like COPD: Airway remodeling
Airway remodeling is a characteristic feature of asthma and has important functional implications. The structural changes include epithelial detachment, subepithelial fibrosis, increased airway smooth muscle (ASM) mass, decreased distance between epithelium and ASM cells, goblet cell hyperplasia, mucus gland hyperplasia, proliferation of blood vessels, airway edema, and changes in cartilage. 53 Each can contribute to airway hyperreactivity (AHR) and may eventually lead to irreversible airflow obstruction with disease progression. 53 In COPD, there is also a thickening of the airway wall, involving the epithelium, reticular basement membrane, ASM, and mucous glands, although it is not as prominent as in asthma. 54 In addition, there is evidence for remodeling, fibrosis, and inflammation in these structures, albeit with patterns different from those seen in asthmatics. [54] [55] [56] Furthermore, bronchodilator reversibility and AHR may be present in a significant proportion of COPD patients. 57 Poorer pulmonary function is associated with a greater magnitude of AHR, and increasing severity of AHR is associated with faster rates of decline in lung function in continuing smokers. 58 Patients with COPD who presented reversibility were often classified as having an 'asthmatic' component in contrast to 'pure' or 'true' COPD. Small-scale clinical trials assessing inhaled steroids in COPD indicated that they should not be prescribed for patients who had no acute response to inhaled bronchodilators or oral corticosteroids. 59 However, many recent studies have suggested that COPD patients without AHR or bronchodilator/oral steroid responses can be treated with these drugs. [60] [61] [62] The relationship between structural alterations and airway responsiveness in COPD patients has been investigated. Chanez et al. 16 reported that COPD patients with asthma-like features such as eosinophilia and airway hyperresponsiveness had thicker basement membranes than COPD patients without these features. There was more ASM in the small airways of COPD patients than in controls, but ASM was less prominent than in asthma. 63 Mathematical modeling has indicated that an increase in muscle mass is the most important contributor to airway hyperresponsiveness. 64 These findings suggest that COPD with airway remodeling is a severe phenotype and part of the overlap between COPD and asthma.
RECENT CONCEPTS FOR ASTHMA AND COPD TREATMENT: COMMON THERAPEUTIC TARGETS
Clinical recognition of the overlap between asthma and COPD is based on inflammatory features. Inflammation in asthma is associated with increased airway hyperresponsiveness, which leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in early morning. 65 This inflammation is present even in those with very mild asthma and is unique in that the airway wall is infiltrated by Th2 lymphocytes, eosinophils, macrophages/monocytes, and mast cells. 65 In contrast, the pathological hallmarks of COPD are destruction of the lung parenchyma (pulmonary emphysema) and inflammation of the peripheral airways (respiratory bronchiolitis) and central airways, along with parenchymal inflammation. 66, 67 There is a marked increase in macrophages and neutrophils in the bronchoalveolar lavage fluid and induced sputum. 66, 67 Given that asthma and COPD are both pulmonary disorders characterized by various degrees of inflammation and tissue remodeling, they present common therapeutic targets. al infections, allergens, cytokines, and growth factors can activate intracellular kinases, following binding to transmembrane receptors on responsive cells. 68 Intracellular kinase pathways play critical roles in a majority of pathobiological events, including transcription, translation, cell migration, apoptosis, and cellular production and secretion of mediators. 69, 70 Studies have focused on the elucidation of these signaling pathways in order to find novel therapeutic targets common to both asthma and COPD. The kinases investigated include mitogen activated protein kinases such as p38, ERK, and JNK; inhibitor of κB kinase 2/NF-κB; phosphoinositol-3 kinase; and signal-specific Janus kinases and signal transducers and activators of transcription. 71 One inflammatory mediator common to both airway diseases is adenosine, making its receptor signaling pathway a therapeutic target for asthma and COPD. Adenosine levels were increased in the plasma, lavage fluid, and exhaled breath condensate of patients with asthma and COPD, and in animal models that exhibited features of chronic airway disease. 72 Moreover, the inhalation of adenosine induced bronchoconstriction in patients with asthma and COPD. 73 A non-selective adenosine receptor antagonist, theophylline, improves lung function and symptoms in asthma and COPD. 72, 73 Furthermore, adenosine receptors are expressed on most, if not all, inflammatory and stromal cell types involved in the pathogenesis of asthma and COPD. Extracellular adenosine elicits its effects by interacting with four adenosine receptors: A1R, A2AR, A2BR, and A3R. 74 Adenosine receptor signaling systems are complex, displaying different and specific actions in various inflammatory responses. Studies in animal models of airway disease have suggested that A1, A3, and A2B antagonists may be useful for the treatment of asthma and COPD, although their therapeutic efficacy remains to be fully evaluated. Various selective adenosine receptor antagonists are under preclinical or clinical studies in patients with asthma and/or COPD.
CONCLUSIONS
Asthma and COPD are complex, multifactorial airway diseases associated with significant morbidity and mortality. Despite their distinct clinical phenotypic features, there is considerable overlap of symptoms and pathogenesis, and several hypotheses have been proposed regarding the status of asthma and COPD as single disease entities. Asthma and COPD may have distinct or common origins; nevertheless, clinical overlap can result owing to similar structural alterations that can develop in both diseases as a consequence of chronic inflammatory tissue injury, especially in the most severe cases. Overlapping features may occur not only in a permanent form but also as a transient symptom, as in exacerbation. In accordance with this, recent therapeutic approaches have concentrated on a target common to the pathogenesis of both asthma and COPD. Possible candidate targets include the adenosine receptor system and various kinase pathways, and many selective inhibitors of adenosine receptors and kinases are in preclinical or clinical trials. There remains a need to extend novel drug development and investigate the mechanisms and treatment of overlapping asthma and COPD.
